Professor Michael Friedlander has an extensive track record of research into gynaecological and breast malignancies, with major focus on innovative clinical trials in ovarian cancer and using patient reported outcomes as endpoints in clinical trials. His extensively cited and influential work has led to important, lasting changes in clinical cancer treatment and improved patient outcomes.
Professor Friedlander is recognised both nationally and internationally and has a long-term track record of effective leadership, training and mentorship in the discipline.